COMMUNIQUÉS West-GlobeNewswire

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Immuneering to Present at the Leerink Global Healthcare Conference
02/03/2026
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that [...]
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
02/03/2026
Fourth Quarter, Full-Year 2025 and Selected Highlights: Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period Full-Year revenue of $272.3 million, a 36% increase [...]
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
02/03/2026
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2025 Results; Sets 2026 Guidance; Announces Share Repurchase Program
02/03/2026
BRENTWOOD, Tenn., March 02, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
02/03/2026
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory [...]
Myriad Commercially Launches Precise MRD with Select Community Oncologists
02/03/2026
Launch Represents Significant Step to Broader Commercialization SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, [...]
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
02/03/2026
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a [...]
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hired non-executive [...]
BrightSpring Announces Secondary Offering of Common Stock and Concurrent Share Repurchase
02/03/2026
LOUISVILLE, Ky., March 02, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex [...]
Alignment Healthcare Announces Secondary Offering
02/03/2026
ORANGE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) (“Alignment Healthcare” or the “Company”), an award-winning Medicare Advantage (MA) company, today announced the commencement [...]
Correction to Company Announcement No. 13 of March 2, 2026
02/03/2026
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - Correction: In Company Announcement no. 13/2026 regarding transactions with shares and linked securities in Genmab A/S made by [...]
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
02/03/2026
CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today [...]
Valneva annonce sa participation à des conférences investisseurs
02/03/2026
Lyon (France), le 2 mars 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des présentations et [...]
Valneva to Participate in Upcoming Investor Conferences
02/03/2026
Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in [...]
Pediatric Home Service Partners with Morgan’s to Expand Prescribed Pediatric Extended Care Services in Texas with New Center, Morgan’s Wonder Care
02/03/2026
SAN ANTONIO, March 02, 2026 (GLOBE NEWSWIRE) -- Pediatric Home Service (PHS), a national provider of comprehensive pediatric healthcare, is partnering with Morgan’s to bring its Prescribed Pediatric Extended Care (PPEC [...]
OSE Immunotherapeutics accélère son recentrage stratégique autour de ses principaux leviers de création de valeur en phase avancée: Lusvertikimab et Tedopi®
02/03/2026
Dépriorisation de certains programmes précoces non stratégiques, conformément au plan stratégique à 3 ans 2026–2028 précédemment annoncé Aucun impact sur la visibilité financière ni sur la stratégie de financement, [...]
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
02/03/2026
Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic plan No impact on cash runway or financing strategy as no milestone associated [...]

Pages